Cooper Richelle J, Gupta Malkeet, Wilkes Michael S, Hoffman Jerome R
Emergency Medicine Center, Los Angeles School of Medicine, University of California, Los Angeles, CA 90024, USA.
J Gen Intern Med. 2006 Dec;21(12):1248-52. doi: 10.1111/j.1525-1497.2006.00598.x.
We undertook this investigation to characterize conflict of interest (COI) policies of biomedical journals with respect to authors, peer-reviewers, and editors, and to ascertain what information about COI disclosures is publicly available.
We performed a cross-sectional survey of a convenience sample of 135 editors of peer-reviewed biomedical journals that publish original research. We chose an international selection of general and specialty medical journals that publish in English. Selection was based on journal impact factor, and the recommendations of experts in the field. We developed and pilot tested a 3-part web-based survey. The survey included questions about the presence of specific policies for authors, peer-reviewers, and editors, specific restrictions on authors, peer-reviewers, and editors based on COI, and the public availability of these disclosures. Editors were contacted a minimum of 3 times.
The response rate for the survey was 91 (67%) of 135, and 85 (93%) of 91 journals reported having an author COI policy. Ten (11%) journals reported that they restrict author submissions based on COI (e.g., drug company authors' papers on their products are not accepted). While 77% report collecting COI information on all author submissions, only 57% publish all author disclosures. A minority of journals report having a specific policy on peer-reviewer 46% (42/91) or editor COI 40% (36/91); among these, 25% and 31% of journals state that they require recusal of peer-reviewers and editors if they report a COI. Only 3% of respondents publish COI disclosures of peer-reviewers, and 12% publish editor COI disclosures, while 11% and 24%, respectively, reported that this information is available upon request.
Many more journals have a policy regarding COI for authors than they do for peer-reviewers or editors. Even author COI policies are variable, depending on the type of manuscript submitted. The COI information that is collected by journals is often not published; the extent to which such "secret disclosure" may impact the integrity of the journal or the published work is not known.
我们开展此项调查,以描述生物医学期刊在作者、同行评审人员和编辑方面的利益冲突(COI)政策,并确定关于COI披露的哪些信息是公开可用的。
我们对135种发表原创研究的同行评审生物医学期刊的编辑进行了便利抽样横断面调查。我们选择了一批以英文出版的综合性和专业性国际医学期刊。选择基于期刊影响因子以及该领域专家的建议。我们开发并进行了预测试一个由三部分组成的网络调查。该调查包括关于作者、同行评审人员和编辑的具体政策的存在情况、基于COI对作者、同行评审人员和编辑的具体限制以及这些披露的公开可用性的问题。至少与编辑联系了3次。
调查的回复率为135份中的91份(67%),91种期刊中有85种(93%)报告有作者COI政策。10种(11%)期刊报告称,他们基于COI限制作者投稿(例如,不接受制药公司作者关于其产品的论文)。虽然77%的期刊报告收集了所有作者投稿的COI信息,但只有57%的期刊公布了所有作者的披露信息。少数期刊报告有针对同行评审人员的具体政策(46%,42/91)或编辑COI政策(40%,36/91);在这些期刊中,25%和31%的期刊表示,如果同行评审人员和编辑报告存在COI,他们要求其回避。只有3%的受访者公布同行评审人员的COI披露信息,12%公布编辑的COI披露信息,而分别有11%和24%的受访者表示可应要求提供此信息。
制定作者COI政策的期刊比制定同行评审人员或编辑COI政策的期刊多得多。即使是作者COI政策也因提交稿件的类型而异。期刊收集的COI信息往往未公布;这种“秘密披露”可能对期刊或已发表作品的完整性产生何种影响尚不清楚。